European and Australian Cooperative Stroke Study II "ECASS-II"

Completed

Phase 3 Results

Results

165 alteplase-group patients and 143 placebo-group patients had favorable MRS outcomes (p=0.277). Outcomes were similar whether patients treated within 0-3 h or 3-6 h with no difference between treatment groups at day 90 +/-14 days.